Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,946
datasets available to search
ShareScore release 0.9.0
Dataset results
5,946 results for “Type 2 diabetes”
Factors Associated with Glycemic Control among Patients with Type 2 Diabetes: A cross-sectional study
Open the record for dataset details and reuse information.
TYPE 2 DIABETES AND ITS IMPACT ON THE IMMUNE SYSTEM
Open the record for dataset details and reuse information.
Datasets for the paper "Regulation of endocrine cell alternative splicing revealed by single-cell RNA sequencing in type 2 diabetes pathogenesis."
Open the record for dataset details and reuse information.
Fetal/maternal-determined birth weight and adulthood type 2 diabetes and its subtypes: a Mendelian randomization study
Open the record for dataset details and reuse information.
Digital coaching strategies to facilitate behavioral change in type 2 diabetes: a systematic review
<p><strong>Context:</strong> In this systematic review, we focus on the clinical impact of digital tools for providing health coaching, education, and facilitating behavior in patients with prediabetes or type 2 diabetes. Our approach was designed to provide insights for clinicians and health care systems that are considering adopting such digital tools. This dataset provides summary information related to the systematic review. </p> <p><strong>Evidence Acquisition:</strong> We searched the CINAHL, Scopus, and Ovid/MEDLINE databases using PRISMA guidelines for studies that reported digital coaching strategies for management and prevention of type 2 diabetes published from January 2014 to June 2019. Articles were reviewed by 2 independent blinded reviewers. Twenty-one articles met inclusion criteria.</p> <p><strong>Evidence Synthesis:</strong> We found that 20 of 21 studies in our analysis showed statistically significant improvements in at least one measure of diabetes control including HbA1c, weight loss, fasting blood glucose, and BMI. Studies that reported weight loss percentage from baseline at 1 year reported values ranging from −3.04% to −8.98%, similar to outcomes with traditional coaching in the Diabetes Prevention Program (N = 4). Additionally, all studies that included a comparison group of in-person or telephone-based coaching showed statistically better or similar outcomes in the digital coaching group (N = 5).</p> <p><strong>Conclusions</strong>: The evidence reported in this systematic review suggests that digital health coaching offers a promising strategy for long-term management and prevention of type 2 diabetes in diverse populations with similar benefits to in-person or telephone-based health coaching. We argue that, with the potential to treat large numbers of individuals in diverse geographic locations, digital coaching offers a promising solution to the rapid increase in diabetes prevalence.</p>
Nonalcoholic fatty liver disease, sleep behaviors, and incident type 2 diabetes
<p><span>Objectives: Nonalcoholic fatty liver disease (NAFLD) is associated with incident type 2 diabetes; however, the extent to which NAFLD may confer its risk remains uncertain, especially in Europeans. Emerging evidence suggests that sleep behaviors are linked to NAFLD and diabetes. We aimed to measure whether sleep behaviors modified the association between NAFLD and incident type 2 diabetes.</span></p> <p><span>Methods: This prospective cohort study included 362,834 participants without type 2 diabetes at baseline in UK Biobank data. Five sleep behaviors, including sleep duration, insomnia, snoring, chronotype, and daytime sleepiness, were collected from the questionnaire. Liver steatosis was based on the fatty liver index.</span></p> <p><span>Results: During a median follow-up of 10.9 years, we documented 7,394 patients with incident type 2 diabetes. NAFLD was significantly associated with increased diabetes risk. Sleeping 7-8 h/day, no insomnia, no self-reported snoring and no frequent daytime sleepiness were independently associated with incident type 2 diabetes, with a 19%, 19%, 13%, and 29% lower risk, respectively. 33.8% and 33.5% of type 2 diabetes events in this cohort could be attributed to NAFLD and poor sleep pattern, respectively. We further found significant interaction between NAFLD and sleep duration and insomnia (<i>P</i> for interaction = 0.027 and 0.025, respectively). Compared those with NAFLD and abnormal sleep duration (≤6 h or ≥9 h) or insomnia, participants with non-NAFLD and normal sleep duration or non-insomnia had 57% (RR 0.43, 95% CI 0.40, 0.47) or 55% (RR 0.45, 95% CI 0.41, 0.50) lower risk of incident diabetes. These associations were independent of age, sex, ethnicity, education, family history, economic status, lifestyles, hemoglobin A1c, systolic blood pressure, total cholesterol, and associated medications.</span></p> <p><span>Conclusion: Both NAFLD and some sleep behaviors were risk factors for type 2 diabetes. Insomnia and sleep duration modified the association between NAFLD and type 2 diabetes.</span></p>
Effects of Myostatin gene knockout on white fat browning and related gene expression in type 2 diabetic mice
<p><strong>Supplementary material</strong></p>
A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)
ClinicalTrials.gov study NCT00110435. IPD Sharing: Not stated. Countries: 0. Publications: 2.
Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria
ClinicalTrials.gov study NCT02807974. IPD Sharing: YES. Countries: 1. Publications: 0.
Effect of 2-Week Nightly Moderate Hypoxia on Glucose Tolerance in Individuals With Type 2 Diabetes
ClinicalTrials.gov study NCT02513641. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
ClinicalTrials.gov study NCT02793154. IPD Sharing: NO. Countries: 1. Publications: 0.
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01022112. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes
ClinicalTrials.gov study NCT03732209. IPD Sharing: NO. Countries: 1. Publications: 0.
Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion
ClinicalTrials.gov study NCT02397447. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
ClinicalTrials.gov study NCT03267576. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
ClinicalTrials.gov study NCT01215097. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Social Support Intervention for Self-management of Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT04491253. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
ClinicalTrials.gov study NCT00374907. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
ClinicalTrials.gov study NCT01408888. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effort During Resistance Training in Type 2 Diabetes
ClinicalTrials.gov study NCT06497842. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.